Market Closed -
Nasdaq
16:00:00 2024-06-12 EDT
5-day change
1st Jan Change
1,028
USD
+1.70%
+2.17%
+17.01%
Sales 2024 *
13.82B
18.99B
Sales 2025 *
14.94B
20.52B
Capitalization
111B
152B
Net income 2024 *
3.97B
5.45B
Net income 2025 *
4.42B
6.08B
EV / Sales 2024 *
7.36
x
Net cash position
2024
*
9.08B
12.48B
Net cash position
2025
*
14.86B
20.42B
EV / Sales 2025 *
6.43
x P/E ratio 2024 *
30.4
x
P/E ratio 2025 *
27.2
x
Employees
13,677
Yield 2024 *
-
Yield 2025 *
-
Free-Float
78.42%
Duration
1 day 1 week 1 month 3 months 6 months 1 year 5 years 10 years
Period
5 minutes 15 minutes 30 minutes 1 hour 1 day 1 week 1 month 1 year
Style
CandleStick End-of-day OHLC Mountain
Dynamic Chart
Wells Fargo Adjusts Price Target on Regeneron Pharmaceuticals to $1,125 From $1,050
06-12
MT
RBC Capital Raises Price Target on Regeneron Pharmaceuticals to $1,229 From $1,200, Maintains Outperform Rating
06-12
MT
Sanofi, Regeneron Secure US FDA Nod for Kevzara’s Use in Polyarticular Juvenile Idiopathic Arthritis
06-11
MT
Transcript : Regeneron Pharmaceuticals, Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-11-2024 08:00 AM
06-11
Regeneron, Sanofi Gain FDA Approval for Kevzara to Treat Juvenile Idiopathic Arthritis
06-11
MT
Regeneron, Sanofi Get Expanded FDA OK for Kevzara in Polyarticular Juvenile Idiopathic Arthritis
06-11
DJ
Regeneron Pharmaceuticals Insider Sold Shares Worth $798,821, According to a Recent SEC Filing
06-10
MT
Regeneron Pharmaceuticals Insider Sold Shares Worth $1,115,422, According to a Recent SEC Filing
06-05
MT
Transcript : Regeneron Pharmaceuticals, Inc. Presents at Jefferies 2024 Global Healthcare Conference, Jun-05-2024 08:30 AM
06-05
RBC Adjusts Price Target on Regeneron Pharmaceuticals to $1,200 From $1,185
06-04
MT
FibroGen Investigational New Drug Application for Cancer Treatment Accepted by FDA; Regeneron Selected as Supplier
06-03
MT
FibroGen To Begin Trials on Tumor Treatment After FDA OK
06-03
DJ
Fibrogen, Inc. Announces Clinical Trial Supply Agreement with Regeneron Pharmaceuticals, Inc. to Evaluate FibroGen's Immuno-Oncology Assets, Fg-3175 (Anti-Ccr8), in Upcoming Clinical Trials
06-03
CI
EMA backs approving Sanofi's Dupixent for 'smoker's lungs', FDA extends review
05-31
RE
Sanofi, Regeneron's Dupixent Receives Recommendation for Approval From European Medicines Agency Committee
05-31
MT
More news
Wells Fargo Adjusts Price Target on Regeneron Pharmaceuticals to $1,125 From $1,050
06-12
MT
RBC Capital Raises Price Target on Regeneron Pharmaceuticals to $1,229 From $1,200, Maintains Outperform Rating
06-12
MT
Regeneron Pharmaceuticals Insider Sold Shares Worth $798,821, According to a Recent SEC Filing
06-10
MT
Regeneron Pharmaceuticals Insider Sold Shares Worth $1,115,422, According to a Recent SEC Filing
06-05
MT
RBC Adjusts Price Target on Regeneron Pharmaceuticals to $1,200 From $1,185
06-04
MT
More recommendations
1 day +1.70%
1 week +2.17%
Current month +4.85%
1 month +5.53%
3 months +5.88%
6 months +18.98%
Current year +17.01%
More quotes
Managers
Title Age Since
Founder
64
88-01-07
Chief Executive Officer
71
88-01-07
Director of Finance/CFO
53
02-12-31
Members of the board
Title Age Since
Director/Board Member
71
10-11-11
Chief Executive Officer
71
88-01-07
Director/Board Member
83
91-05-31
More insiders
Date
Price
Change
Volume
24-06-12
1,028
+1.70%
453,603
24-06-11
1,011
+0.88%
448,231
24-06-10
1,002
-0.12%
250,886
24-06-07
1,003
+0.22%
250,100
24-06-06
1,001
-0.51%
439,791
Delayed Quote
Nasdaq, June 12, 2024 at 04:00 pm
More quotes
Regeneron Pharmaceuticals, Inc. specializes in research, development, producing, and selling drugs used in treating ophthalmologic and inflammatory diseases and cancers. Net sales break down by type of revenue as follows:
- revenues from product sales (56.6%);
- revenues from collaboration agreements (40.4%): collaboration with Sanofi (58.1% of revenues), Bayer (29.1%) and Roche (12.8%);
- other (3%): primarily revenues from sales of technology licenses and subcontracted research services.
At the end of 2022, the group had a portfolio of approximately 35 products in clinical development.
More about the company
Last Close Price
1,028
USD
Average target price
1,047
USD
Spread / Average Target
+1.91%
Consensus
1st Jan change
Capi.
+17.01% 109B +16.93% 124B -7.23% 23.84B +1.98% 22.42B -14.29% 17.5B -6.79% 16.61B -37.63% 16.43B +2.17% 13.4B +24.42% 11.47B +98.94% 9.98B
Bio Therapeutic Drugs
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1